For metastatic prostate cancer, current standard of treatment consists of a combination of androgen-receptor inhibitors and taxanes (51), which leaves platinating and alkylating agents open as an alternative treatment option, or as an adjuvant therapy. Here, AR is linked to metastatic prostate carcinoma.